NCT05523401View on ClinicalTrials.gov

Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 16, 2023

Primary Completion Date

October 20, 2024

Study Completion Date

November 5, 2024

Conditions
Healthy
Interventions
DRUG

4-bromo-2,5-dimethoxyphenethylamine (10 mg)

A low dose of 10 mg 2C-B will be administered.

DRUG

4-bromo-2,5-dimethoxyphenethylamine (20 mg)

A medium dose of 20 mg 2C-B will be administered.

DRUG

4-bromo-2,5-dimethoxyphenethylamine (30 mg)

A high dose of 30 mg 2C-B will be administered.

DRUG

3,4-methylenedioxymethamphetamine

A moderate dose of 125 mg MDMA will be administered.

DRUG

Psilocybin

A moderate dose of 25 mg psilocybin will be administered.

OTHER

Placebo

Placebo (Mannitol)

Trial Locations (1)

Unknown

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER